Core Viewpoint - The collaboration between Sanofi and Pfizer for the dual-specific antibody SSGJ-707 marks a significant step in the global commercialization of innovative cancer therapies, enhancing the international recognition and accessibility of Sanofi's products [1][2]. Company Summary - Sanofi and its affiliates granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the dual-specific antibody SSGJ-707, with Pfizer retaining rights for commercialization in mainland China through additional payments [1]. - Pfizer will pay an upfront non-refundable fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales share based on product sales in authorized regions [1]. - The antibody SSGJ-707 targets PD-1 and VEGF, having received breakthrough therapy designation from the National Medical Products Administration for treating advanced non-small cell lung cancer (NSCLC) [1][2]. Industry Summary - The collaboration signifies recognition of Sanofi's dual-specific antibody research platform by a leading international company, which is expected to enhance the global reach and acceptance of its products [2]. - The SSGJ-707 is currently in Phase III clinical trials for NSCLC and Phase II for other indications, indicating a robust pipeline for Sanofi's innovative therapies [2]. - The trend of Chinese innovative drug companies entering into licensing agreements with multinational pharmaceutical companies is growing, driven by the increasing recognition of Chinese innovation and the need for multinational firms to address patent cliffs [3][4].

证券代码： 688336 证券简称：三生国健 公告编号：2025-023 三生国健药业（上海）股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据上海证券交易所相关规定，公司对相关问题进行了自查，并 发函向公司控股股东及实际控制人核实。现将有关情况： 说明如下： 处的行业政策未发生重大调整。 ? 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）股票交易连续两个交易日内（2025 年 5 月 19 日、2025 年 易所交易规则》 《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 ? 经公司自查并向控股股东及实际控制人核实，截止本公告披露 日，除公司已披露信息外，公司及公司控股股东、实际控制人不存在 筹划关于公司的应披露而未披露的重大事项的情况，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 ? 公司及本公司的关联方三生制药和沈阳三生制药有限责任公 司（以下简称"沈阳三生"，以下合称"许可方 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-022 三生国健药业（上海）股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 5 日 至2025 年 6 月 5 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时间为股东大会召开当日的交易时间段， 即 9:15-9:25,9:30-11:30， 的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票 程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通 投资者的投票，应按照《上海证券交易所科创板上市公司自律监管指 引第 ...

证券代码： 688336 证券简称：三生国健 公告编号：2025-023 三生国健药业（上海）股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）股票交易连续两个交易日内（2025 年 5 月 19 日、2025 年 5 月 20 日）日收盘价格涨幅偏离值累计超过 30%，根据《上海证券交 易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》 的有关规定，属于股票交易异常波动情形。 经公司自查并向控股股东及实际控制人核实，截止本公告披露 日，除公司已披露信息外，公司及公司控股股东、实际控制人不存在 筹划关于公司的应披露而未披露的重大事项的情况，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 公司及本公司的关联方三生制药和沈阳三生制药有限责任公 司（以下简称"沈阳三生"，以下合称"许可方"）共同授予被许可 方辉瑞公司（Pfizer Inc.）（以下简称"被许可方"）在许可区域 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-022 三生国健药业（上海）股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 5 日 10 点 00 分 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 股东大会召开日期：2025年6月5日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 （七） 涉及公开征集股东投票权 不涉及。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | | | 投票股东类型 | | --- | --- ...

Market Overview - A-shares experienced a broad rally on May 20, with overall market activity increasing and trading volume expanding, as both A-shares and Hong Kong stocks rose over 1% [1] - The three major A-share indices saw significant gains, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component Index up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 12.114 trillion yuan, an increase of 923 billion yuan compared to the previous day [1] Pet Economy Concept - The pet economy concept surged, with over 3800 stocks in the market showing gains, including Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high, and Lusi Co. (832419) also hitting a limit up [2][4] - The pet market has been maintaining high growth rates, benefiting from domestic brand replacement effects and continuous improvements in product and brand strength, leading to significant year-on-year sales increases [4][6] - Analysts expect the pet sector's performance to continue reaching new highs in 2024 and the first quarter of 2025, driven by stable overseas orders and the growth of domestic pet food brands [6] Innovative Drug Concept - The innovative drug concept saw a strong performance, with significant gains in stocks such as Sangfor Biopharma (01530) which rose over 32%, and other companies like Rongchang Biopharma (688331) and Yifang Biopharma (688382) also experiencing substantial increases [8][10] - Sangfor Biopharma announced a collaboration with Pfizer for the exclusive global development rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [8][10] - The innovative drug sector is expected to benefit from potential changes in international drug pricing strategies, which may position China as a low-cost research and production center [13] Shipping Concept - The shipping sector experienced a significant pullback, with stocks like Guohang Ocean (833171) dropping nearly 18%, and several others hitting the daily limit down [15][16] - Despite the recent downturn, companies like Lianyungang (601008) and Ningbo Ocean (601022) have reassured investors that their operations remain normal and that there are no significant changes in industry policies [17]

Market Overview - A-shares experienced a broad rally on May 20, with the Shanghai Composite Index closing up 0.38% at 3380.48 points, the Shenzhen Component up 0.77% at 10249.17 points, and the ChiNext Index up 0.77% at 2048.46 points. The total trading volume across the three exchanges reached 121.14 billion yuan, an increase of 9.23 billion yuan from the previous day [1][2]. Pet Economy - The pet economy concept saw significant gains, with Tianyuan Pet (301335) hitting a 20% limit up and reaching a new high. Lusi Co. (832419) also hit a limit up, marking a new high. Other companies in this sector, such as Bei Yin Mei (002570) and Yi Yi Co. (001206), also experienced limit up [4][5][6]. - Analysts noted that the pet market has maintained high growth rates in recent years, benefiting from domestic brand replacement effects and improvements in product and brand strength. This has led to significant year-on-year sales growth and price increases for domestic brands [7]. Innovative Drug Sector - The innovative drug sector showed strong performance, with Yipin Hong (300723) and San Sheng Guo Jian (688336) both hitting the 20% limit up. Other companies like Rongchang Bio (688331) and Yifang Bio (688382) saw increases of approximately 16% [8][9]. - San Sheng Guo Jian announced a collaboration with Pfizer for the exclusive global development and commercialization rights of a dual-target antibody, SSGJ-707, which has shown promising results in clinical trials for non-small cell lung cancer [10][11]. Shipping Sector - The shipping sector experienced a significant pullback, with companies like Guo Hang Yuan Yang (833171) dropping nearly 18%, and others such as Fenghuang Shipping (000520) and Lianyungang (601008) hitting their daily limit down [16][17]. - Lianyungang, which had seen five consecutive limit up days, reported a 48.01% year-on-year decline in net profit for the first quarter of 2025, raising concerns among investors [18][19].

5月20日，A股主要指数震荡上行，沪指收涨0.38%报3380点，深证成指涨0.77%，创业板指涨0.77%，北证50指数涨1.22%创历史新高。 全天成交1.21万亿元，较前一交易日增量923亿元，全市场超3800股上涨。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 上证指数 | Friend | 3380.48 | +12.90 | 40.38% | | 000001 | Now | | | | | 创业板指 | | 2048.46 | +15.70 | +0.77% | | 399006 | | | | | | 深证成指 | | 10249.17 | +78.08 +0.77% | | | 100002 | AF | | | | 盘面上，新消费方向走强，宠物经济板块持续爆发，盲盒经济、谷子经济板块走高，培育钻石板块拉升，家用轻工板块走强，美容护理、人造肉 及珠宝首饰等板块涨幅居前。另外，航运港口板块下挫，PEEK材料板块走低，航天航空、碳纤维、可控核聚变及钛白粉等板块跌幅居前。 | 行业热力图 v 领涨板块 | | | | | ...

Market Performance - The three major A-share indices all rose, with the Shanghai Composite Index up 0.38%, the Shenzhen Component Index up 0.77%, and the ChiNext Index also up 0.77 [1][2] Consumer Sector - The consumer sector showed strong performance today, particularly in areas such as the pet economy, cultivated diamonds, beauty care, and millet economy, which had the highest gains [1][2] - Analysts noted that consumer demand is diversifying, with emotional, health, and beauty consumption needs continuing to evolve, leading to ongoing opportunities in single product categories like pet products and snacks [2] Beauty Care Sector - According to Zhonghang Securities, the beauty care sector is expected to see structural opportunities due to favorable policies, restored consumer confidence, and technological innovations [2] - The upcoming "618" shopping festival and optimized brand promotion strategies are seen as short-term catalysts for the beauty care sector [2] Pet Economy Sector - CITIC Securities forecasts that the pet economy sector will continue to grow through 2025, highlighting its resilience and the potential for increased market concentration as the industry matures [2] - The domestic market is currently characterized by "large industry, small leaders," suggesting that leading companies can enhance market share through product innovation, branding, and channel development [2] Pharmaceutical Sector - Pharmaceutical stocks surged today, with Sanofi's stock hitting the daily limit, marking two consecutive trading days of gains [3] - Sanofi announced a collaboration with Pfizer, granting exclusive rights for the development, production, and commercialization of a product, with an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [3] Market Highlights - CATL's listing on the Hong Kong stock market saw significant gains, while its A-share rose by 1.15% [3] - Some high-profile stocks experienced volatility, with companies like Lijun Co., Youfu Co., and Ningbo Ocean facing significant declines [3]

Group 1 - The core viewpoint indicates that the domestic innovation opportunities outweigh challenges, with a potential shift towards "source innovation" and integration into the global industrial chain restructuring [3] - The ChiNext Composite Index ETF (Hua Xia) closely tracks the performance of the ChiNext Composite Index, reflecting the overall performance of eligible companies listed on the ChiNext board, including dividend income [4] - Recent performance shows that the ChiNext Composite Index ETF has seen a 1.19% increase over the past month, with a trading volume of 1.07 billion yuan and a turnover rate of 3.9% [3] Group 2 - The Chinese innovative drug sector is characterized by low R&D costs and high efficiency, positioning it as a preferred choice for business development transactions, with China expected to become a low-cost R&D and production center [4] - The CXO industry chain in China is likely to strengthen its market position as multinational pharmaceutical companies seek to reduce R&D and production costs under stricter pricing systems [4] - There are investment opportunities in segments such as innovative drugs, medical devices, traditional Chinese medicine, medical services, and chain pharmacies [4]